{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:21:06Z","timestamp":1788481266064,"version":"build-2803163510"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T00:00:00Z","timestamp":1751846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Nanjing Second Hospital Talent Promotion Project","award":["No. RCMS232013"],"award-info":[{"award-number":["No. RCMS232013"]}]},{"name":"Geriatric Health Research Project of Jiangsu Provincial Health Commission","award":["No. LKM2022037"],"award-info":[{"award-number":["No. LKM2022037"]}]},{"name":"Key Project of Research Project of Jiangsu Provincial Health Commission","award":["No. K2023018"],"award-info":[{"award-number":["No. K2023018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-10271-z","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:13:54Z","timestamp":1751915634000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mechanism of Brucea javanica against multiple myeloma via TNF-NF-\u03baB signaling"],"prefix":"10.1038","volume":"15","author":[{"given":"Yuan","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoda","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyi","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,7]]},"reference":[{"key":"10271_CR1","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1159\/000520312","volume":"44","author":"M Heider","year":"2021","unstructured":"Heider, M., Nickel, K., Hogner, M. & Bassermann, F. Multiple myeloma: molecular pathogenesis and disease evolution. Oncol. Res. Treat. 44, 672\u2013681. https:\/\/doi.org\/10.1159\/000520312 (2021).","journal-title":"Oncol. Res. Treat."},{"key":"10271_CR2","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/S2352-3026(21)00057-0","volume":"8","author":"N van de Donk","year":"2021","unstructured":"van de Donk, N., Usmani, S. Z. & Yong, K. CAR T-cell therapy for multiple myeloma: state of the Art and prospects. Lancet Haematol. 8, e446\u2013e461. https:\/\/doi.org\/10.1016\/S2352-3026(21)00057-0 (2021).","journal-title":"Lancet Haematol."},{"key":"10271_CR3","doi-asserted-by":"publisher","unstructured":"Goel, U., Usmani, S. & Kumar, S. Current approaches to management of newly diagnosed multiple myeloma. Am. J. Hematol. 97 (Suppl 1). https:\/\/doi.org\/10.1002\/ajh.26512 (2022).","DOI":"10.1002\/ajh.26512"},{"key":"10271_CR4","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1038\/s41408-021-00432-4","volume":"11","author":"E Terpos","year":"2021","unstructured":"Terpos, E. et al. Management of patients with multiple myeloma beyond the clinical-trial setting: Understanding the balance between efficacy, safety and tolerability, and quality of life. Blood Cancer J. 11, 40. https:\/\/doi.org\/10.1038\/s41408-021-00432-4 (2021).","journal-title":"Blood Cancer J."},{"key":"10271_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/ajco.13459","volume":"17","author":"Y Bai","year":"2021","unstructured":"Bai, Y. & Su, X. Updates to the drug-resistant mechanism of proteasome inhibitors in multiple myeloma. Asia-Pac. J. Clin. Oncol. 17, 29\u201335. https:\/\/doi.org\/10.1111\/ajco.13459 (2021).","journal-title":"Asia-Pac. J. Clin. Oncol."},{"key":"10271_CR6","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.3389\/fphar.2018.01233","volume":"9","author":"Q Wang","year":"2018","unstructured":"Wang, Q. et al. Maintenance chemotherapy with Chinese herb medicine formulas vs. with placebo in patients with advanced Non-small cell lung Cancer after First-Line chemotherapy: A multicenter, randomized, Double-Blind trial. Front. Pharmacol. 9, 1233. https:\/\/doi.org\/10.3389\/fphar.2018.01233 (2018).","journal-title":"Front. Pharmacol."},{"key":"10271_CR7","doi-asserted-by":"publisher","unstructured":"Mao, D. et al. Meta-analysis of Xihuang pill efficacy when combined with chemotherapy for treatment of breast cancer. Evid. Based Complement. Alternat.  Med. 2019 (3502460). https:\/\/doi.org\/10.1155\/2019\/3502460 (2019).","DOI":"10.1155\/2019\/3502460"},{"key":"10271_CR8","doi-asserted-by":"publisher","first-page":"D1197","DOI":"10.1093\/nar\/gkaa1063","volume":"49","author":"S Fang","year":"2021","unstructured":"Fang, S. et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 49, D1197\u2013D1206. https:\/\/doi.org\/10.1093\/nar\/gkaa1063 (2021).","journal-title":"Nucleic Acids Res."},{"key":"10271_CR9","doi-asserted-by":"publisher","first-page":"106954","DOI":"10.1016\/j.phrs.2023.106954","volume":"197","author":"Y Wang","year":"2023","unstructured":"Wang, Y. et al. Efficacy and safety of Gutong patch compared with NSAIDs for knee osteoarthritis: A real-world multicenter, prospective cohort study in China. Pharmacol. Res. 197, 106954. https:\/\/doi.org\/10.1016\/j.phrs.2023.106954 (2023).","journal-title":"Pharmacol. Res."},{"key":"10271_CR10","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1292\/jvms.09-0508","volume":"72","author":"S Bawm","year":"2010","unstructured":"Bawm, S. et al. Evaluation of Myanmar medicinal plant extracts for antitrypanosomal and cytotoxic activities. J. Vet. Med. Sci. 72, 525\u2013528. https:\/\/doi.org\/10.1292\/jvms.09-0508 (2010).","journal-title":"J. Vet. Med. Sci."},{"key":"10271_CR11","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jep.2017.01.042","volume":"198","author":"YF Huang","year":"2017","unstructured":"Huang, Y. F. et al. Anti-inflammatory effects of Brucea Javanica oil emulsion by suppressing NF-kappaB activation on dextran sulfate sodium-induced ulcerative colitis in mice. J. Ethnopharmacol. 198, 389\u2013398. https:\/\/doi.org\/10.1016\/j.jep.2017.01.042 (2017).","journal-title":"J. Ethnopharmacol."},{"key":"10271_CR12","doi-asserted-by":"publisher","first-page":"853119","DOI":"10.3389\/fphar.2022.853119","volume":"13","author":"J Zhang","year":"2022","unstructured":"Zhang, J. et al. Major constituents from Brucea Javanica and their Pharmacological actions. Front. Pharmacol. 13, 853119. https:\/\/doi.org\/10.3389\/fphar.2022.853119 (2022).","journal-title":"Front. Pharmacol."},{"key":"10271_CR13","doi-asserted-by":"publisher","first-page":"153560","DOI":"10.1016\/j.phymed.2021.153560","volume":"86","author":"KW Li","year":"2021","unstructured":"Li, K. W. et al. Brucea javanica: A review on anticancer of its Pharmacological properties and clinical researches. Phytomedicine 86, 153560. https:\/\/doi.org\/10.1016\/j.phymed.2021.153560 (2021).","journal-title":"Phytomedicine"},{"key":"10271_CR14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1080\/15384047.2016.1210737","volume":"17","author":"ME Issa","year":"2016","unstructured":"Issa, M. E., Berndt, S., Carpentier, G., Pezzuto, J. M. & Cuendet, M. Bruceantin inhibits multiple myeloma cancer stem cell proliferation. Cancer Biol. Ther. 17, 966\u2013975. https:\/\/doi.org\/10.1080\/15384047.2016.1210737 (2016).","journal-title":"Cancer Biol. Ther."},{"key":"10271_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.2147\/DDDT.S155244","volume":"12","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Enhanced gastric therapeutic effects of Brucea Javanica oil and its gastroretentive drug delivery system compared to commercial products in pharmacokinetics study. Drug Des. Devel Ther. 12, 535\u2013544. https:\/\/doi.org\/10.2147\/DDDT.S155244 (2018).","journal-title":"Drug Des. Devel Ther."},{"key":"10271_CR16","doi-asserted-by":"publisher","first-page":"108612","DOI":"10.1016\/j.biopha.2019.108612","volume":"112","author":"M Imran","year":"2019","unstructured":"Imran, M. et al. Luteolin, a flavonoid, as an anticancer agent: A review. Biomed. Pharmacother. 112, 108612. https:\/\/doi.org\/10.1016\/j.biopha.2019.108612 (2019).","journal-title":"Biomed. Pharmacother"},{"key":"10271_CR17","doi-asserted-by":"publisher","first-page":"4196","DOI":"10.3892\/mmr.2015.3956","volume":"12","author":"L Ma","year":"2015","unstructured":"Ma, L. et al. Luteolin exerts an anticancer effect on NCI-H460 human non-small cell lung cancer cells through the induction of Sirt1-mediated apoptosis. Mol. Med. Rep. 12, 4196\u20134202. https:\/\/doi.org\/10.3892\/mmr.2015.3956 (2015).","journal-title":"Mol. Med. Rep."},{"key":"10271_CR18","doi-asserted-by":"publisher","first-page":"14448","DOI":"10.4238\/2015.November.18.7","volume":"14","author":"JX Niu","year":"2015","unstructured":"Niu, J. X., Guo, H. P., Gan, H. M., Bao, L. D. & Ren, J. J. Effect of Luteolin on gene expression in mouse H22 hepatoma cells. Genet. Mol. Res. 14, 14448\u201314456. https:\/\/doi.org\/10.4238\/2015.November.18.7 (2015).","journal-title":"Genet. Mol. Res."},{"key":"10271_CR19","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1182\/blood.V100.6.2263","volume":"100","author":"K Neben","year":"2002","unstructured":"Neben, K. et al. Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100, 2263\u20132265 (2002).","journal-title":"Blood"},{"key":"10271_CR20","doi-asserted-by":"publisher","first-page":"e060923220758","DOI":"10.2174\/1874467217666230908111754","volume":"17","author":"SM Manohar","year":"2024","unstructured":"Manohar, S. M. At the crossroads of TNF alpha signaling and Cancer. Curr. Mol. Pharmacol. 17, e060923220758. https:\/\/doi.org\/10.2174\/1874467217666230908111754 (2024).","journal-title":"Curr. Mol. Pharmacol."},{"key":"10271_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu, H., Lin, L., Zhang, Z., Zhang, H. & Hu, H. Targeting NF-kappaB pathway for the therapy of diseases: mechanism and clinical study. Signal. Transduct. Target. Ther. 5, 209. https:\/\/doi.org\/10.1038\/s41392-020-00312-6 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10271_CR22","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/j.biopha.2017.08.120","volume":"95","author":"M Hu","year":"2017","unstructured":"Hu, M. et al. IL-1beta-induced NF-kappaB activation down-regulates miR-506 expression to promotes osteosarcoma cell growth through JAG1. Biomed. Pharmacother. 95, 1147\u20131155. https:\/\/doi.org\/10.1016\/j.biopha.2017.08.120 (2017).","journal-title":"Biomed. Pharmacother"},{"key":"10271_CR23","doi-asserted-by":"publisher","unstructured":"Musolino, C. et al. Inflammatory and Anti-Inflammatory equilibrium, proliferative and antiproliferative balance: the role of cytokines in multiple myeloma. Mediators Inflamm. 2017 (1852517). https:\/\/doi.org\/10.1155\/2017\/1852517 (2017).","DOI":"10.1155\/2017\/1852517"},{"key":"10271_CR24","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.stem.2024.06.007","volume":"31","author":"C Zhou","year":"2024","unstructured":"Zhou, C. et al. Nynrin preserves hematopoietic stem cell function by inhibiting the mitochondrial permeability transition pore opening. Cell. Stem Cell. 31, 1359\u20131375e1358. https:\/\/doi.org\/10.1016\/j.stem.2024.06.007 (2024).","journal-title":"Cell. Stem Cell."},{"key":"10271_CR25","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res. 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res."},{"key":"10271_CR26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/imr.12233","volume":"263","author":"Y Kawano","year":"2015","unstructured":"Kawano, Y. et al. Targeting the bone marrow microenvironment in multiple myeloma. Immunol. Rev. 263, 160\u2013172. https:\/\/doi.org\/10.1111\/imr.12233 (2015).","journal-title":"Immunol. Rev."},{"key":"10271_CR27","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1385\/MO:19:3","volume":"19","author":"V Jurisic","year":"2002","unstructured":"Jurisic, V. & Colovic, M. Correlation of Sera TNF-alpha with percentage of bone marrow plasma cells, LDH, beta2-microglobulin, and clinical stage in multiple myeloma. Med. Oncol. 19, 133\u2013139. https:\/\/doi.org\/10.1385\/MO:19:3 (2002).","journal-title":"Med. Oncol."},{"key":"10271_CR28","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3109\/10428194.2014.956313","volume":"56","author":"XS Wang","year":"2015","unstructured":"Wang, X. S. et al. Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leuk. Lymphoma. 56, 1335\u20131341. https:\/\/doi.org\/10.3109\/10428194.2014.956313 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"10271_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.phrs.2016.06.018","volume":"111","author":"P Poornima","year":"2016","unstructured":"Poornima, P., Kumar, J. D., Zhao, Q., Blunder, M. & Efferth, T. Network Pharmacology of cancer: from Understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol. Res. 111, 290\u2013302. https:\/\/doi.org\/10.1016\/j.phrs.2016.06.018 (2016).","journal-title":"Pharmacol. Res."},{"key":"10271_CR30","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s13020-023-00853-2","volume":"18","author":"L Li","year":"2023","unstructured":"Li, L. et al. Network pharmacology: a bright guiding light on the way to explore the personalized precise medication of traditional Chinese medicine. Chin. Med. 18, 146. https:\/\/doi.org\/10.1186\/s13020-023-00853-2 (2023).","journal-title":"Chin. Med."},{"key":"10271_CR31","doi-asserted-by":"publisher","unstructured":"Jang, D. I. et al. The role of tumor necrosis factor alpha (TNF-alpha) in autoimmune disease and current TNF-alpha inhibitors in therapeutics. Int. J. Mol. Sci. 22 https:\/\/doi.org\/10.3390\/ijms22052719 (2021).","DOI":"10.3390\/ijms22052719"},{"key":"10271_CR32","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1016\/j.ejca.2013.07.010","volume":"49","author":"M Tsubaki","year":"2013","unstructured":"Tsubaki, M. et al. Inhibition of the tumour necrosis factor-alpha autocrine loop enhances the sensitivity of multiple myeloma cells to anticancer drugs. Eur. J. Cancer. 49, 3708\u20133717. https:\/\/doi.org\/10.1016\/j.ejca.2013.07.010 (2013).","journal-title":"Eur. J. Cancer"},{"key":"10271_CR33","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41590-021-00931-3","volume":"22","author":"MME de Jong","year":"2021","unstructured":"de Jong, M. M. E. et al. The multiple myeloma microenvironment is defined by an inflammatory stromal cell landscape. Nat. Immunol. 22, 769\u2013780. https:\/\/doi.org\/10.1038\/s41590-021-00931-3 (2021).","journal-title":"Nat. Immunol."},{"key":"10271_CR34","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1002\/ijc.34214","volume":"151","author":"Q Wang","year":"2022","unstructured":"Wang, Q., Shi, Q., Lu, J., Wang, Z. & Hou, J. Causal relationships between inflammatory factors and multiple myeloma: A bidirectional Mendelian randomization study. Int. J. Cancer. 151, 1750\u20131759. https:\/\/doi.org\/10.1002\/ijc.34214 (2022).","journal-title":"Int. J. Cancer"},{"key":"10271_CR35","doi-asserted-by":"publisher","unstructured":"Cetinkaya, M. & Baran, Y. Therapeutic potential of luteolin on cancer. Vaccines (Basel)  11. https:\/\/doi.org\/10.3390\/vaccines11030554 (2023).","DOI":"10.3390\/vaccines11030554"},{"key":"10271_CR36","doi-asserted-by":"publisher","first-page":"e26701","DOI":"10.1016\/j.heliyon.2024.e26701","volume":"10","author":"A Rauf","year":"2024","unstructured":"Rauf, A. et al. Revisiting luteolin: an updated review on its anticancer potential. Heliyon 10, e26701. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e26701 (2024).","journal-title":"Heliyon"},{"key":"10271_CR37","doi-asserted-by":"publisher","first-page":"3705","DOI":"10.31557\/APJCP.2023.24.11.3705","volume":"24","author":"S Kapoor","year":"2023","unstructured":"Kapoor, S., Gupta, N. & Sharma, A. A. Polyherbal Ashwagandha formulation exhibits adjunctive antitumor efficacy against U266 myeloma cells by Multi-Strategic cytotoxic effects: an experimental approach. Asian Pac. J. Cancer Prev. 24, 3705\u20133714. https:\/\/doi.org\/10.31557\/APJCP.2023.24.11.3705 (2023).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10271_CR38","doi-asserted-by":"publisher","first-page":"e399","DOI":"10.1038\/bcj.2016.7","volume":"6","author":"P de la Puente","year":"2016","unstructured":"de la Puente, P. et al. MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma. Blood Cancer J. 6, e399. https:\/\/doi.org\/10.1038\/bcj.2016.7 (2016).","journal-title":"Blood Cancer J."},{"key":"10271_CR39","doi-asserted-by":"publisher","first-page":"3567","DOI":"10.1016\/j.apsb.2022.03.020","volume":"12","author":"X Wang","year":"2022","unstructured":"Wang, X., Hua, P., He, C. & Chen, M. Non-apoptotic cell death-based cancer therapy: molecular mechanism, Pharmacological modulators, and nanomedicine. Acta Pharm. Sin B. 12, 3567\u20133593. https:\/\/doi.org\/10.1016\/j.apsb.2022.03.020 (2022).","journal-title":"Acta Pharm. Sin B"},{"key":"10271_CR40","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.blre.2018.11.003","volume":"34","author":"D Vrabel","year":"2019","unstructured":"Vrabel, D., Pour, L. & Sevcikova, S. The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 34, 56\u201366. https:\/\/doi.org\/10.1016\/j.blre.2018.11.003 (2019).","journal-title":"Blood Rev."},{"key":"10271_CR41","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1007\/s13277-015-3322-5","volume":"36","author":"YW Jeon","year":"2015","unstructured":"Jeon, Y. W., Ahn, Y. E., Chung, W. S., Choi, H. J. & Suh, Y. J. Synergistic effect between celecoxib and Luteolin is dependent on Estrogen receptor in human breast cancer cells. Tumour Biol. 36, 6349\u20136359. https:\/\/doi.org\/10.1007\/s13277-015-3322-5 (2015).","journal-title":"Tumour Biol."},{"key":"10271_CR42","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1158\/1535-7163.MCT-09-0191","volume":"8","author":"Q Zhou","year":"2009","unstructured":"Zhou, Q. et al. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol. Cancer Ther. 8, 1684\u20131691. https:\/\/doi.org\/10.1158\/1535-7163.MCT-09-0191 (2009).","journal-title":"Mol. Cancer Ther."},{"key":"10271_CR43","first-page":"65","volume":"10","author":"M Jourdan","year":"1999","unstructured":"Jourdan, M. et al. Tumor necrosis factor is a survival and proliferation factor for human myeloma cells. Eur. Cytokine Netw. 10, 65\u201370 (1999).","journal-title":"Eur. Cytokine Netw."},{"key":"10271_CR44","doi-asserted-by":"publisher","first-page":"5673","DOI":"10.1038\/sj.onc.1205664","volume":"21","author":"CS Mitsiades","year":"2002","unstructured":"Mitsiades, C. S. et al. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1\/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 21, 5673\u20135683. https:\/\/doi.org\/10.1038\/sj.onc.1205664 (2002).","journal-title":"Oncogene"},{"key":"10271_CR45","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1002\/eji.1830190903","volume":"19","author":"G Lonnemann","year":"1989","unstructured":"Lonnemann, G. et al. Differences in the synthesis and kinetics of release of Interleukin 1 alpha, Interleukin 1 beta and tumor necrosis factor from human mononuclear cells. Eur. J. Immunol. 19, 1531\u20131536. https:\/\/doi.org\/10.1002\/eji.1830190903 (1989).","journal-title":"Eur. J. Immunol."},{"key":"10271_CR46","doi-asserted-by":"publisher","unstructured":"Liu, J. et al. ERK signaling mediates resistance to Immunomodulatory drugs in the bone marrow microenvironment. Sci. Adv. 7 https:\/\/doi.org\/10.1126\/sciadv.abg2697 (2021).","DOI":"10.1126\/sciadv.abg2697"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10271-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10271-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10271-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T19:13:55Z","timestamp":1751915635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-10271-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,7]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10271"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-10271-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,7]]},"assertion":[{"value":"16 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Medical Ethics Committee of Nanjing Second Hospital (No. 2023-LY-ky-015).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Brucea javanica has been checked with WFO (2024): Brucea javanica (L.) Merr. Published on the Internet;. Accessed on: 28 Dec 2024\u2019.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Plant name information"}}],"article-number":"24311"}}